Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials

6 Aug 2015

Abstract excerpt

Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Prostate Cancer Treatment and Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26622323
DOI: 10.1177/1756287215597637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trialsPMID 26622323Read ↗

Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate CancerSemantic proximity Read ↗

Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancerSemantic proximity Read ↗

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.Semantic proximity Read ↗

The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancerSemantic proximity Read ↗

Epigenetic regulation of androgen receptor signaling in prostate cancerSemantic proximity Read ↗

Progress in the mechanism and drug development of castration-resistant prostate cancer.Semantic proximity Read ↗

[Molecular biology of castration-resistant prostate cancer].Semantic proximity Read ↗

Development and prevalence of castration-resistant prostate cancer subtypesSemantic proximity Read ↗

The epigenetic function of androgen receptor in prostate cancer progressionSemantic proximity Read ↗

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate CancerSemantic proximity Read ↗

Epigenetic modulators as therapeutic targets in prostate cancerSemantic proximity Read ↗

[Current status of castration resistant prostate cancer basic research].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.